DRI Capital to float pharma royalties fund in London
Canada’s DRI Capital is preparing to list a new fund on the London Stock Exchange focused on investing in pharmaceuticals royalties.
In an intention to float document, DRI Healthcare, as the new closed end fund will be known, said it would raise $350m by selling new shares to institutional investors. Jefferies is global co-ordinator, Numis Securities is bookrunner and sponsor.The proceeds of the transaction will be used to ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org